Disease · HP_0100607
Targets28
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 28
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PTGS2 | Cyclooxygenase | 14 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Approval | https://conductscience.org/library/genes/5743 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 11 | Cyclooxygenase inhibitor | Approval | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PGR | Progesterone receptor | 7 | Progesterone receptor agonist; Progesterone receptor antagonist | Approval | https://conductscience.org/library/genes/5241 | Drugs and targets |
| ESR1 | Estrogen receptor | 3 | Estrogen receptor alpha agonist | Approval | https://conductscience.org/library/genes/2099 | Drugs and targets |
| HTR1B | 5-hydroxytryptamine receptor 1B | 2 | Serotonin 1b (5-HT1b) receptor agonist | Phase 3 | https://conductscience.org/library/genes/3351 | Drugs and targets |
| HTR1D | 5-hydroxytryptamine receptor 1D | 2 | Serotonin 1d (5-HT1d) receptor agonist | Phase 3 | https://conductscience.org/library/genes/3352 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist; Glucocorticoid receptor antagonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | 1 | Arachidonate 5-lipoxygenase inhibitor | Approval | https://conductscience.org/library/genes/240 | Drugs and targets |
| AVPR1A | Vasopressin V1a receptor | 1 | Vasopressin V1a receptor antagonist | Phase 1 | https://conductscience.org/library/genes/552 | Drugs and targets |
| FAAH | Fatty-acid amide hydrolase 1 | 1 | Anandamide amidohydrolase inhibitor | Approval | https://conductscience.org/library/genes/2166 | Drugs and targets |
| GNRHR | Gonadotropin-releasing hormone receptor | 1 | Gonadotropin-releasing hormone receptor antagonist | Phase 3 | https://conductscience.org/library/genes/2798 | Drugs and targets |
| HRH2 | Histamine H2 receptor | 1 | Histamine H2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3274 | Drugs and targets |
| MTNR1A | Melatonin receptor | 1 | Melatonin receptor agonist | Phase 2 | https://conductscience.org/library/genes/4543 | Drugs and targets |
| MTNR1B | Melatonin receptor | 1 | Melatonin receptor agonist | Phase 2 | https://conductscience.org/library/genes/4544 | Drugs and targets |
| NR3C2 | Mineralocorticoid receptor | 1 | Mineralocorticoid receptor antagonist | Approval | https://conductscience.org/library/genes/4306 | Drugs and targets |
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | 1 | Phosphodiesterase 5A inhibitor | Phase 1 | https://conductscience.org/library/genes/8654 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6326 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/HP_0100607/targets